GlaxoSmithKline seeks U.S., European marketing approval for rhinitis intranasal treatment

By Elaine Rigoli

Tampa, Fla., July 27 - GlaxoSmithKline has submitted applications for both U.S. and European marketing approval for a new medicine to treat the symptoms of seasonal allergic rhinitis and perennial allergic rhinitis.

The company said the medicine (fluticasone furoate) is an enhanced affinity intranasal corticosteroid with the proposed name of Allermist in the United States and Avamys in Europe.

The efficacy and safety of Allermist/Avamys have been evaluated in seven clinical trials with 2,555 adult and pediatric patients two years of age and older with rhinitis symptoms.

GlaxoSmithKline is a pharmaceutical company located in Middlesex, U.K.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.